In March, the FDA cleared Dexcom’s Stelo, making it the first glucose biosensor that doesn’t require a prescription. The small, wearable device, worn on the back of the upper arm, is designed ...

Ithaka US Growth Strategy highlighted stocks like DexCom, Inc. (NASDAQ:DXCM), in the third quarter 2024 investor letter. DexCom, Inc. (NASDAQ:DXCM) is a medical device company that develops and ...

Aristotle Focus Growth Strategy highlighted stocks like DexCom, Inc. (NASDAQ:DXCM), in the third quarter 2024 investor letter. DexCom, Inc. (NASDAQ:DXCM) is a medical device company that develops ...

Artisan Mid Cap Fund highlighted stocks like DexCom, Inc. (NASDAQ:DXCM), in the third quarter 2024 investor letter. DexCom, Inc. (NASDAQ:DXCM) is a medical device company that engages in the ...

Dexcom enjoys a well-established track record for introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, Dexcom has captured an ...

DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries ...

Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous ...

CVS Health Chief Executive Officer Karen Lynch has stepped down as the top executive and will be replaced by David Joyner, who has been in charge of the company’s Caremark pharmacy benefit firm ...

The company has also been evaluating whether its pharmacy benefits manager unit, CVS Caremark, which manages drug benefits for health plans, should be housed within the retail unit or under ...

CVS Health has a new CEO: David Joyner, a seasoned veteran in the healthcare industry, is stepping into the challenging role. He takes the helm during a turbulent period for CVS, as it grapples ...

The Caremark pharmacy benefits management business that Joyner led is under scrutiny from the Federal Trade Commission, which alleged CVS and its rivals drove up insulin prices. Congress is ...